ZENAS BIOPHARMA, INC. COMMON STOCK
NASDAQ: ZBIO (Zenas BioPharma, Inc.)
Kemas kini terakhir: 1 jam lalu31.65
-0.64 (-1.98%)
| Penutupan Terdahulu | 32.29 |
| Buka | 32.40 |
| Jumlah Dagangan | 480,995 |
| Purata Dagangan (3B) | 849,941 |
| Modal Pasaran | 2,062,843,264 |
| Harga / Jualan (P/S) | 1.73 |
| Harga / Buku (P/B) | 8.53 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| Margin Operasi (TTM) | -373.30% |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 6.47 |
| Aliran Tunai Operasi (OCF TTM) | -137.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.73 M |
| Pulangan Atas Aset (ROA TTM) | -56.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zenas BioPharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.50 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.20% |
| % Dimiliki oleh Institusi | 74.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nvp Associates, Llc | 30 Jun 2026 | 1,838,482 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |